{"id":"NCT01777321","sponsor":"GlaxoSmithKline","briefTitle":"Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years","officialTitle":"Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Versus Intramuscularly in Adults Aged 50 Years or Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-17","primaryCompletion":"2013-10-10","completion":"2014-11-11","firstPosted":"2013-01-28","resultsPosted":"2017-01-06","lastUpdate":"2018-10-25"},"enrollment":60,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Zoster"],"interventions":[{"type":"BIOLOGICAL","name":"Herpes zoster vaccine GSK1437173A","otherNames":[]}],"arms":[{"label":"SC HZ/su Group","type":"EXPERIMENTAL"},{"label":"IM HZ/su Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of GSK Biologicals' Herpes Zoster (HZ) vaccine (GSK 1437173A) when administered subcutaneously (SC) as compared to intramuscularly (IM) to people 50 years of age and older.","primaryOutcome":{"measure":"Number of Subjects With Anti-Glycoprotein E (Anti-gE) Antibody Concentrations Higher Than or Equal to (≥)18 Milli-international Units Per Milliliter (mIU/mL)","timeFrame":"Before vaccination (PRE), two months after Dose 1 (M2) and one month after Dose 2 (M3)","effectByArm":[{"arm":"SC GSK1437173A Group","deltaMin":29,"sd":null},{"arm":"IM GSK1437173A Group","deltaMin":29,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":16},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["37781954","27936344"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":30},"commonTop":["Pain","Redness","Fatigue","Swelling","Injection site pruritus"]}}